Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025

Core Insights - Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and other diseases related to dysregulated aldosterone [1][3] Financial Results Announcement - The company will report its financial results for the fourth quarter and full year ended December 31, 2024, before the markets open on February 12, 2025 [1] Conference Call Details - A live conference call will take place on February 12 at 8:30 a.m. ET, with domestic and international dial-in numbers provided [2] Company Overview - Mineralys Therapeutics is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor aimed at treating cardiorenal conditions influenced by dysregulated aldosterone [3]